Table 1.

Recommendations for perioperative use of targeted therapy in patients with SpA

Drugs	Dosing interval	Recommended timing for elective surgery (since the last dose administered)
Infliximab	Every 4, 6, or 8 weeks	Week 5, 7, or 9
Abatacept	Monthly (intravenous injection), or weekly (subcu- taneous injection)	Week 5 (intravenous injection), or week 2 (subcutaneous injection)
Certolizumab pegol	Every 2 or 4 weeks	Week 3, or 5
Rituximab	2 doses 2 weeks apart every 4~6 months	Month 5, or 7
Tocilizumab	Every week (subcutaneous injection), or every 4 weeks (intravenous injection)	Week 2 (subcutaneous injection), or week 5 (intravenous injection)
Secukinumab	Every 4 weeks	Week 5
Ustekinumab	Every 12 weeks	Week 13
Ixekizumab	Every 4 weeks	Week 5
Guselkumab	Every 8 weeks	Week 9
Tofacitinib	Daily, or twice daily	Day 4
Upadacitinib	Daily	Day 4